louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02326714: Auricular Acupressure (AA) For Overweight/Obese Adolescent and Young Polycystic Ovary Syndrome ( PCOS)
Official title: Effect of Auricular Acupressure on Overweight/Obese Adolescent and Young Women With Polycystic Ovary Syndrome.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Polycystic Ovary Syndrome
Lead sponsor: Heilongjiang University of Chinese Medicine
Sponsor class: OTHER
First posted: 2014-12-29
Enrollment: 120
Sex: FEMALE
Minimum age (years): 12
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to investigate the effect and safety of auricular acupressure on adolescent and young women with PCOS. Subjects will be randomly assigned in to two arms: Auricular acupressure arm and placebo auricular acupressure, both arms will be treated for three months. Body mass index, oral glucose tolerance test, hormonal profile and metabolic profile will be determined.


Eligibility criteria: Inclusion Criteria:

* Women aged between 12 and 25 years.
* Diagnosis of PCOS according to the modified Rotterdam criteria.
* 2 years after menarche.
* Body mass index (BMI) equal to or greater than 23 kg/m\*m.

Exclusion Criteria:

* Administration of other medications known to affect reproductive function or metabolism within the past three months, including oral contraceptives, Gonadotropin-releasing hormone (GnRH) agonists and antagonists, anti androgens, gonadotropins, anti-obesity drugs, Chinese herbal medicines, anti diabetic drugs such as metformin and thiazolidinediones, somatostatin, diazoxide, and calcium channel blockers.
* Patients with other endocrine disorders including 21-hydroxylase deficiency, hyperprolactinemia, uncorrected thyroid disease, suspected Cushing's syndrome.
* Patients with known severe organ dysfunction or mental illness.

Primary outcomes:
measure: Body mass index (BMI): BMI change at 3 months.
timeFrame: 3 month
Secondary outcomes:
measure: Oral glucose tolerance test (OGTT)
timeFrame: 3 month
measure: Testosterone (T)
timeFrame: 3 month
measure: Sex hormone-binding globulin (SHBG)
timeFrame: 3 month
measure: Dehydroepiandrosterone sulfate (DHEAS).
timeFrame: 3 month
measure: Follicle stimulating hormone (FSH)
timeFrame: 3 month
measure: Luteinizing hormone (LH)
timeFrame: 3 month
measure: Cholesterol
timeFrame: 3 month
measure: Triglycerides (TG)
timeFrame: 3 month
measure: Waist/hip ratio
timeFrame: 3 month
measure: Ferriman-Gallwey score
timeFrame: 3 month
Other outcomes:
Locations:
city: Harbin
country: China
facility: First Affiliated Hospital, Heilongjiang University of Chinese Medicine
state: Heilongjiang
Study officials:
affiliation: First Affiliated Hospital of Heilongjiang University Of Chinese
name: Lihui Hou, Bachelor
role: STUDY_CHAIR
References:
Clinical trial NCT06867614: Laparoscopic Versus Transvaginal Closure of the Vaginal Vault After Total Laparoscopic Hysterectomy
Official title: Laparoscopic Versus Transvaginal Closure of the Vaginal Vault After Total Laparoscopic Hysterectomy - a Single Blinded Randomized Comparative Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Total Laparoscopic Hysterectomy
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2025-03-10
Enrollment: 48
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: The goal of this clinical trial is to compare the laparoscopic and transvaginal closure techniques of the vaginal vault in patients who perform TLH, regarding the risk of vaginal vault hematoma and other complications as vaginal cuff infection and sexual dysfunction.


Eligibility criteria: Inclusion Criteria:

* Adult females consenting to do TLH all age groups with diagnoses of benign uterine conditions.
* Women who are non-obese (normal or overweight women with BMI range 18-29.9).
* Sexually active female.

Exclusion Criteria:

* Diagnosed cases of pelvic malignancy
* Diagnosed patients with Cervical intraepithelial neoplasia (CIN) or bacterial vaginosis (any infection should be treated)
* Obese patients.
* Patients currently undergoing treatment for any type of cancer
* Patients with coagulopathy, bleeding/clotting disorders
* Patients with any condition can impair wound healing: diabetes mellites, anemia, steroids
* Patients with a previous history of radiation and allergy to sutures
* Patients with clinically evident prolapse

Primary outcomes:
measure: Vaginal Vault hematoma
timeFrame: From 10 days postoperative to 30 days postoperative
Secondary outcomes:
measure: Bleeding/spotting
timeFrame: From 10 days postoperative to 30 days postoperative
measure: Vaginal infection:
timeFrame: From 10 days postoperative to 30 days postoperative
measure: Vaginal prolapse
timeFrame: From 10 days postoperative to 30 days postoperative
measure: Vaginal cuff granulation
timeFrame: From 10 days postoperative to 30 days postoperative
measure: Sexual dysfunction
timeFrame: From 3 to 4 months post operative
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University maternity hospital
Study officials:
References:
Clinical trial NCT05566314: Beverage for Immune Support
Official title: Amunizer for Immune Support: A Randomized, Placebo Controlled, Double Blind Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Immune
Lead sponsor: Nutraceuticals Research Institute
Sponsor class: OTHER
First posted: 2022-10-04
Enrollment: 160
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Evaluate the effects of a beverage supplement on immune health over an 8 week intervention using either a placebo or active supplement.


Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

-

Primary outcomes:
measure: Number of days with symptoms documented by the Franklin Health Immune Inventory (FHII)
timeFrame: from baseline to the end of the study, 8 weeks
measure: Severity of symptoms documented by the FHII
timeFrame: from baseline to the end of the study, 8 weeks
Secondary outcomes:
measure: Incidence and severity on the upper respiratory symptom subscale of the FHII
timeFrame: from baseline to the end of the study, 8 weeks
measure: Incidence and severity on the gastrointestinal symptom subscale of the FHII
timeFrame: from baseline to the end of the study, 8 weeks
measure: Incidence and severity on the dermal symptom subscale of the FHII
timeFrame: from baseline to the end of the study, 8 weeks
measure: Change from baseline scores on the Franklin Energy Level Inventory
timeFrame: 8 week
measure: Change from baseline scores on the Franklin Sleep Quality Inventory
timeFrame: 8 week
measure: Change from baseline scores on the Franklin Mood Scale
timeFrame: 8 week
Other outcomes:
Locations:
city: Franklin
country: United States
facility: Franklin Health Research Center
state: Tennessee
Study officials:
References:
Clinical trial NCT06532214: Clinical Retrospective Study Analysis of Postoperative Complications Following Hepatectomy
Official title: Clinical Retrospective Study Analysis of Postoperative Complications Following Hepatectomy
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Liver Failure
Liver Dysfunction
Keywords: hepatectomy
liver failure
Post-hepatectomy liver failure
Lead sponsor: Nanfang Hospital, Southern Medical University
Sponsor class: OTHER
First posted: 2024-08-01
Enrollment: 2000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients who underwent liver resection surgery at the participating centers

Brief summary: Hepatectomy is a crucial surgical method for treating liver diseases such as liver cancer, hepatic hemangiomas, and biliary stones. Although hepatectomy has achieved significant therapeutic effects, postoperative complications remain an inevitable issue. Complications following hepatectomy include liver failure, hepatic vascular thrombosis, wound infection at the hepatic incision, and bile leakage, among others. These complications pose a serious threat to patients' health and life, and also increase the waste of medical resources and the cost of treatment. Currently, research on postoperative complications of hepatectomy mainly focuses on small sample studies from a single center, and most studies only focus on a specific complication, lacking comprehensive and systematic analysis. Therefore, it is necessary to conduct a retrospective study analysis of complications related to hepatectomy to more comprehensively and objectively understand the incidence, risk factors, prevention, and treatment of postoperative complications, providing clinical doctors with more scientific treatment plans and guidance.


Eligibility criteria: Inclusion Criteria:

* 1. Patients aged 18-80 years 2.Patients who underwent liver resection surgery at the participating centers

Exclusion Criteria:

* Exclusion criteria are as follows:

  1. Prior cancer treatments such as transarterial chemoembolization, ablation, or targeted therapy.
  2. Repeat liver resection surgeries.
  3. Presence of other malignancies.
  4. Concurrent end-stage diseases including active infections, respiratory failure, decompensated heart failure, and autoimmune disease exacerbations.
  5. Inadequate clinical data availability in medical records.

Primary outcomes:
measure: Post-hepatectomy liver failure (PHLF)
timeFrame: On and after the 5th postoperative day
Secondary outcomes:
measure: mortality
timeFrame: During 30 days after surgery
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Nanfang Hospital
state: Guangdong
Study officials:
References:
Clinical trial NCT06209814: Evaluation of Open-face Maxillary Complete Denture for Patients With Prominent Premaxilla
Official title: Evaluation of Open-face Maxillary Complete Denture for Patients With Prominent Premaxilla. Crossover Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Edentulous Jaw
Keywords: Prominent Premaxilla
Lead sponsor: Alexandria University
Sponsor class: OTHER
First posted: 2024-01-18
Enrollment: 38
Sex: ALL
Minimum age (years): 45
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The aim of the present study was to evaluate open faced maxillary complete denture with soft acryl resin wing versus conventional heat cured maxillary complete denture regarding the retention and patient satisfaction.


Eligibility criteria: Inclusion Criteria:

* Completely edentulous male patients.
* Patients having had no previous complete dentures
* Patients with well-developed edentulous ridge with proclined premaxilla covered with healthy firm mucosa
* Patients with normal Angle Class 1 maxillomandibular relationship

Exclusion Criteria:

* Patients with resorbed ridges
* Patients with xerostomia and patients undertaking medications that affect salivary flow (e.g., diuretics). Similarly, patients with systemic diseases that may affect the amount or consistency of saliva (e.g., uncontrolled diabetes mellitus).

Primary outcomes:
measure: Denture retention
timeFrame: up to 45 days
measure: Patient satisfaction with esthetics
timeFrame: up to 45 days
measure: Patient satisfaction with comfort
timeFrame: up to 45 days
Secondary outcomes:
Other outcomes:
Locations:
city: Alexandria
country: Egypt
facility: Faculty of Dentistry, Alexandria University
Study officials:
affiliation: Alexandria University
name: Haitham A Ismail, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Alexandria University
name: Ingy S Soliman, PhD
role: STUDY_CHAIR
affiliation: Alexandria University
name: Muhammed B El-Danasory, PhD
role: STUDY_CHAIR
affiliation: Alexandria University
name: Salma S Abolgheit, PhD
role: STUDY_CHAIR
References:
Clinical trial NCT01590914: Brain Activation in Response to Appetitive Cues Pre- and Post- Bariatric Surgery
Official title: Brain Activation in Response to Appetite Cues Pre- and Post- Bariatric Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Keywords: Roux-en-Y Bariatric surgery,
Gastric banding,
fMRI,
food cues
Lead sponsor: New York Obesity and Nutrition Research Center
Sponsor class: OTHER
Collaborators: name: St. Luke's-Roosevelt Hospital Center
name: Columbia University
First posted: 2012-05-03
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: Utilizing fMRI, this study will examine changes in BOLD signal as a proxy measure of brain activation in response to highly palatable (high energy density \[kcal/g\]), less palatable and non-food stimuli in severely obese women pre, 1 month post and 3 months post undergoing bariatric surgery (in surgery patients) and at equivalent times for control groups in fed and fasted conditions at each time point.

Two surgical groups: (i) laparoscopic Roux-en-Y gastric bypass (RYGB) and (ii) gastric banding (GB) will be compared with two control groups: (i)those enrolled on a 3-month formula weight loss program or (ii) those who qualify, but do not undergo bariatric surgery, and receive no weight loss treatment.


Eligibility criteria: Inclusion Criteria:

* Age \> 18 and \< 65 years
* BMI \> 40 and \< 50kg/m2
* Right handed
* Good comprehension of English

Exclusion Criteria:

* \> 5% weight fluctuation in the past 3 months
* Presence of disease (including diabetes)
* Pregnancy, lactation or planning to become pregnant in next 18mon
* Smoking, or or recent (within past 12 month) smoking cessation
* Consumption of \> 3 alcoholic beverages per day
* Left handed

Primary outcomes:
measure: BOLD signal response to visual and auditory food cues
timeFrame: pre-surgery, 1mo post and 3mo post surgery
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: St Luke's Roosevelt Hospital Center
state: New York
city: New York
country: United States
facility: Columbia University Medical Center
state: New York
Study officials:
affiliation: New York Nutrition & Obesity Research Center
name: Allan Geliebter, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04294914: Catastrophizing and Virtual Reality's Impact on Pain in Patients With Fibromyalgia
Official title: Catastrophizing and Virtual Reality's Impact on the Pain Threshold During a Cold Pressor Test in Patients With Fibromyalgia: A Case-control Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fibromyalgia
Pain
Lead sponsor: Aalborg University
Sponsor class: OTHER
Collaborators: name: Naestved Hospital
First posted: 2020-03-04
Enrollment: 44
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Half the participants will start with intervention 1 after which they will crossover to intervention 2. The other half will start start with intervention 2 before crossing over to intervention 1.
Primary purpose: BASIC_SCIENCE

Brief summary: This study evaluates the potential association between Virtual Reality, pain catastrophizing thoughts and pain measures in fibromyalgia.


Eligibility criteria: Inclusion Criteria:

* Able to understand, read and speak Danish
* Able to independently answer a questionnaire
* Able to give informed consent

Fibromyalgia group:

* Confirmed diagnosed with fibromyalgia

Controls:

* Healthy participants

Exclusion Criteria:

Applies for both groups:

* Signs of anxiety, depression and post-traumatic stress syndrome that require treatment
* Neurologic, musculoskeletal or mental illnesses that could influence the results.
* Parallel participating in other studies, that can influence this study
* Pregnancy

Fibromyalgia group:

* Regulation in medication
* Anticonvulsivant use the last week
* Serotonin-norepinephrine reuptake Inhibitor (SNRI) the last two weeks
* Tricykliske antidepressants (TCA) the last four weeks

Controls:

* No regular use of pain medication
* No current or previous history of subacute or ongoing pain

Primary outcomes:
measure: Pain intensity
timeFrame: through study completion, an average of 90minutes
measure: Pain threshold
timeFrame: through study completion, an average of 90minutes
measure: Pain tolerance
timeFrame: through study completion, an average of 90minutes
Secondary outcomes:
measure: Pain catastrophizing
timeFrame: through study completion, an average of 90minutes
Other outcomes:
Locations:
city: Naestved
country: Denmark
facility: Interdisciplinary Paincenter Naestved, Naestved hospital
state: Zealand
Study officials:
affiliation: Dept. Of Health Science and Technology, Aalborg University
name: Steffan WM Christensen, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03108014: Beginnings Study Follow Up
Official title: Beginnings Study Follow Up
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Healthy
Lead sponsor: Arkansas Children's Hospital Research Institute
Sponsor class: OTHER
First posted: 2017-04-11
Enrollment: 191
Sex: ALL
Minimum age (years): 14
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Former Beginnings participants at age 14

Brief summary: This study will help us learn more about how early infant diet may influence child's growth and development at age 14.

Detailed description: This study is to follow the infants that were enrolled in Beginnings study which purpose was to characterize physical growth, body composition, dietary intake, neurobehavioral development, and brain function of infants and children fed mostly breast milk, milk based formula, or soy based formula during their first year of life up to age 6. This study will call back those children when they turn 14 to compare growth, sexual maturation, and development between the three diets.

Eligibility criteria: Inclusion Criteria:

* Beginnings study former participants

Exclusion Criteria:

* Dropped participants for medical diagnosis or medical conditions

Primary outcomes:
measure: Growth and development
timeFrame: 14 years
Secondary outcomes:
Other outcomes:
Locations:
city: Little Rock
country: United States
facility: Arkansas Children's Nutrition Center
state: Arkansas
Study officials:
affiliation: Arkansas Children's Nutrition Center
name: Aline a, PhD, RD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05912114: Effectiveness of Mannitol Versus Polyethylene Glycol Electrolyte Dispersion as a Salve for Patients With Inadequate Bowel Preparation: a Randomized Controlled Clinical Trial
Official title: Effectiveness of 1L Mannitol Versus 1L Polyethylene Glycol Electrolyte Dispersion as a Salve for Patients With Inadequate Bowel Preparation: a Randomized Controlled Clinical Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Bowel Cleansing; Good Taste
Lead sponsor: Ningbo No. 1 Hospital
Sponsor class: OTHER
First posted: 2023-06-22
Enrollment: 134
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: For patients with inadequate bowel preparation, current guidelines recommend either remedial measures or rescheduling the endoscopy, but previous surveys have found that approximately 30% of patients do not follow medical advice to reschedule the examination if it is rescheduled, while those who take remedial measures on the same day are more compliant, so remedial measures may be a better option than rescheduling the examination. As for the remedy regimen, it has been demonstrated that oral PEG is superior to the enema regimen in terms of bowel cleansing, but PEG is very resistant to be taken by most patients due to its poor taste and the larger doses required, resulting in poor bowel preparation and poor compliance. In contrast, oral mannitol has the advantages of small dose and good taste, and patient compliance may be higher.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18-75 years with a pre-first colonoscopy bowel cleanliness of less than 2 points in any segment of the bowel.

Exclusion Criteria:

- (1) Pregnant women. (2) History of colorectal surgery. (3) Patients with acute exacerbation of inflammatory bowel disease. (4) Patients with severe medical conditions that make them unsuitable for colonoscopy.

(5) Patients with known allergy to mannitol/PEG. (6) Patients who refuse to sign the informed consent form.

Primary outcomes:
measure: Bowel cleanliness
timeFrame: 1 hour
Secondary outcomes:
measure: Patients' feelings
timeFrame: 1 hour
Other outcomes:
measure: Patients' willingness to take such measures again.
timeFrame: 1 hour
Locations:
city: Ningbo
country: China
facility: Ningbo first hospital
state: Zhejiang
Study officials:
References:
Clinical trial NCT00219414: Study for the Treatment of Ulcerative Colitis With Adacolumn (Companion to US Study 512-04-205)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Ulcerative Colitis
Lead sponsor: Otsuka Frankfurt Research Institute GmbH
Sponsor class: INDUSTRY
First posted: 2005-09-22
Enrollment: 42
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to demonstrate the safety and effectiveness of the Adacolumn Apheresis System to treat the signs and symptoms of ulcerative colitis.

Detailed description: Study Type: Interventional Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study.


Primary outcomes:
measure: Primary Outcomes: Effectiveness will be primarily evaluated at Week 12 by disease activity index (DAI) score; Safety will be evaluated by determining the frequency and severity of adverse events.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: IBD-unit, Dept. of Gastroenterology, HMQ Sophia Hospital, Stockholm, Sweden
name: Robert Lofberg, Prof.
role: PRINCIPAL_INVESTIGATOR
affiliation: Keio University, Tokyo, Japan
name: Toshifumi Hibi, Prof.
role: PRINCIPAL_INVESTIGATOR
References: